

Special Issue

Novel Therapeutic Targets for Metastatic Lung Cancer

Message from the Guest Editor

Metastatic lung cancer remains a leading cause of cancer-related mortality worldwide, with limited curative options. Recent advances in molecular profiling and immuno-oncology have revealed a variety of novel therapeutic targets beyond classical oncogene drivers, including epigenetic regulators, tumor microenvironment components, and emerging resistance pathways. This Special Issue aims to provide an overview of innovative approaches and recent breakthroughs in identifying and targeting novel vulnerabilities in metastatic lung cancer. We welcome original research articles, reviews, and perspectives exploring new molecular targets, mechanisms of resistance, biomarker development, and strategies to enhance treatment efficacy and overcome immune evasion. Contributions from both preclinical and clinical settings are encouraged.

Guest Editor

Dr. Andrea De Giglio

1. Department of Medical and Surgical Sciences, University of Bologna, 40138 Bologna, Italy
2. Medical Oncology, IRCCS Azienda Ospedaliero, Universitaria di Bologna, 40138 Bologna, Italy

Deadline for manuscript submissions

closed (31 December 2025)



Cancers

an Open Access Journal
by MDPI

Impact Factor 4.4
CiteScore 9.0
Indexed in PubMed



mdpi.com/si/238958

Cancers
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
cancers@mdpi.com

[mdpi.com/journal/
cancers](https://mdpi.com/journal/cancers)





Cancers

an Open Access Journal
by MDPI

Impact Factor 4.4
CiteScore 9.0
Indexed in PubMed



[mdpi.com/journal/
cancers](https://mdpi.com/journal/cancers)



About the Journal

Message from the Editor-in-Chief

Cancers (ISSN 2072-6694) is an international, online journal addressing both clinical and basic science issues related to cancer research. The journal will continue its open access format, which will certainly evolve to ensure that the journal takes full advantage of the rapidly changing world of information and knowledge dissemination. It publishes high-quality clinical, translational, and basic science research on cancer prevention, initiation, progression, and treatment, as well as other related topics, particularly to capture the most seminal studies in the rapidly growing area of immunology, immunotherapy, and tumor microenvironment.

Editor-in-Chief

Prof. Dr. Samuel C. Mok

Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA

Author Benefits

Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q2 (Oncology) / CiteScore - Q1 (Oncology)